What is the Return on Assets (ROA) of Novo Nordisk A/S this year?
The Return on Assets (ROA) of Novo Nordisk A/S is 0.22 undefined this year.
In 2025, Novo Nordisk A/S's return on assets (ROA) was 0.22, a -18.52% increase from the 0.27 ROA in the previous year.
Novo Nordisk A/S's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Comparing Novo Nordisk A/S's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Investors consider Novo Nordisk A/S's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Variations in Novo Nordisk A/S’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
The Return on Assets (ROA) of Novo Nordisk A/S is 0.22 undefined this year.
The ROA of Novo Nordisk A/S has increased by -18.52% compared to the previous year.
A high ROA is advantageous for investors of Novo Nordisk A/S, as it indicates that the company efficiently utilizes its assets and generates good profits.
A low ROA can be unfavorable for investors of Novo Nordisk A/S as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
An increase in ROA of Novo Nordisk A/S can be an indicator of improved efficiency in asset utilization and higher profitability.
A reduction in the ROA of Novo Nordisk A/S can be an indicator of lower asset efficiency and profitability.
Some factors that can influence the ROA of Novo Nordisk A/S include revenue, operating costs, asset structure, and industry average.
The ROA of Novo Nordisk A/S is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
To improve ROA, Novo Nordisk A/S can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
Over the past 12 months, Novo Nordisk A/S paid a dividend of 10.41 DKK . This corresponds to a dividend yield of about 1.65 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 10.98 DKK.
The current dividend yield of Novo Nordisk A/S is 1.65 %.
Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of April, September, September, April.
Novo Nordisk A/S paid dividends every year for the past 26 years.
For the upcoming 12 months, dividends amounting to 10.98 DKK are expected. This corresponds to a dividend yield of 1.74 %.
Novo Nordisk A/S is assigned to the 'Health' sector.
To receive the latest dividend of Novo Nordisk A/S from 4/1/2025 amounting to 7.9 DKK, you needed to have the stock in your portfolio before the ex-date on 3/28/2025.
The last dividend was paid out on 4/1/2025.
In the year 2024, Novo Nordisk A/S distributed 14.15 DKK as dividends.
The dividends of Novo Nordisk A/S are distributed in DKK.
The Novo Nordisk A/S stock can be added to a savings plan with the following providers: ING and Consorsbank
Our stock analysis for Novo Nordisk A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novo Nordisk A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.